Oncolytics Biotech Inc将启动二线KRAS突变MSS型MCRC的对照研究,中期数据预计2026年底前公布

美股速递
Feb 04

生物技术公司Oncolytics Biotech Inc宣布,将针对二线KRAS突变、微卫星稳定(MSS)型转移性结直肠癌(MCRC)患者开展一项对照临床研究。该研究的初步中期数据预计最晚于2026年底前获得。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10